Pharvaris
PHVS
106 hedge funds and large institutions have $1.64B invested in Pharvaris in 2025 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 42 increasing their positions, 15 reducing their positions, and 6 closing their positions.
417% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 6
180% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 15
50% more funds holding in top 10
Funds holding in top 10: 8 → 12 (+4)
28% more funds holding
Funds holding: 83 → 106 (+23)
14% more capital invested
Capital invested by funds: $1.44B → $1.64B (+$195M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2.02M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$16.5M |
| 2 |
EP
Eversept Partners
New York
|
+$10.6M |
| 3 |
BlackRock
New York
|
+$7.08M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$6.66M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$6.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$45.8M |
| 2 |
VA
VR Adviser
New York
|
-$16.8M |
| 3 |
CC
Commodore Capital
New York
|
-$12.7M |
| 4 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$9.13M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.75M |
PHVS Hedge Fund Activity: Q4 2025 in Review
106 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Pharvaris (PHVS) for Q4 2025, worth a combined $1.64B — up 14% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PHVS positions and 6 closed out — a net gain of 25 holders — while 42 added to existing stakes and 15 trimmed.
The largest buyer was Deerfield Management, adding an estimated $16.5M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $45.8M sold.
- 106 institutional investors held Pharvaris (PHVS) as of Q4 2025, up from 83 in Q3 2025.
- Funds reported $1.64B of Pharvaris stock for Q4 2025, up 14% quarter-over-quarter.
- 31 funds opened new Pharvaris positions in Q4 2025 and 6 closed out, a net change of +25 holders.
- The largest Pharvaris buyer in Q4 2025 was Deerfield Management, an estimated $16.5M added.
- The largest Pharvaris seller in Q4 2025 was Paradigm Biocapital Advisors, an estimated $45.8M sold.
Based on aggregated 13F filings for Q4 2025.